<DOC>
	<DOCNO>NCT00808418</DOCNO>
	<brief_summary>This aim study determine safety tolerability elesclomol sodium escalating dos ( ultimately identify maximum tolerate dose ) combine fix dose docetaxel concomitant prednisone . This study also characterize pharmacokinetics elesclomol docetaxel .</brief_summary>
	<brief_title>A Study Determine Maximum Tolerated Dose Elesclomol Sodium Given With Fixed Dose Docetaxel Prednisone Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>This aim study determine safety tolerability elesclomol sodium escalating dos ( ultimately identify maximum tolerate dose ) combine fix dose docetaxel concomitant prednisone . This study also characterize pharmacokinetics elesclomol docetaxel .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Inclusion Criteria Confirmed metastatic prostate cancer No one prior chemotherapy disease progress ECOG performance status less equal 2 Adequate bone marrow , renal hepatic function define protocol Neuropathy le equal 2 Reliable venous access frequent study drug infusion Exclusion Criteria Significant cardiovascular disease Known active brain metastasis Subjects receive treatment malignancy past 5 year Other clinically significant uncontrolled condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>castration</keyword>
	<keyword>refractory</keyword>
	<keyword>elesclomol</keyword>
	<keyword>sodium</keyword>
	<keyword>docetaxel</keyword>
	<keyword>prednisone</keyword>
</DOC>